Lordick, Florian and Ridwelski, Karsten and Al-Batran, Salah-Eddin and Trarbach, Tanja and Schlag, Peter M. and Piso, Pompiliu (2008) Treatment of Gastric Cancer. ONKOLOGIE, 31. pp. 32-39. ISSN 0378-584X,
Full text not available from this repository. (Request a copy)Abstract
Even though adjuvant systemic therapy significantly increases 5-year survival rates for resectable gastric or gastroesophageal carcinoma, quality assurance research has shown that in practice it is often not given. The European standard, perioperative chemotherapy, is based on results of the MAGIC trial (3 cycles of ECF - epirubicin, cisplatin, 5-FU as infusion before and after surgery). It is to be expected that oral capecitabine will replace infusional 5-FU in perioperative treatment, as in the palliative setting. This change has already taken place in many institutions. For metastatic and locally advanced esophageal and gastric carcinoma, the results of clinical trials over recent years have led to the following concrete changes: the importance of platinum has been confirmed. Oxaliplatin can replace cisplatin. Capecitabine can replace 5-FU. If docetaxel is given in addition to platinum/5-FU, this doubles 2-year survival (with significant toxicity). Targeted drugs such as cetuximab, panitumumab, and bevacizumab are currently undergoing clinical trials.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | ARBEITSGEMEINSCHAFT-INTERNISTISCHE-ONKOLOGIE; ADVANCED ESOPHAGOGASTRIC CANCER; PHASE-II TRIAL; GASTROESOPHAGEAL JUNCTION; 1ST-LINE THERAPY; ADENOCARCINOMA; CISPLATIN; CHEMOTHERAPY; FLUOROURACIL; SURGERY; |
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Lehrstuhl für Chirurgie |
| Depositing User: | Dr. Gernot Deinzer |
| Date Deposited: | 23 Nov 2020 07:44 |
| Last Modified: | 23 Nov 2020 07:44 |
| URI: | https://pred.uni-regensburg.de/id/eprint/31741 |
Actions (login required)
 |
View Item |
